[State and development of the progeny of rats subjected to androgen skin application in the course of the entire pregnancy]. 1978

M I Golubeva, and L F Shashkina, and M V Starkov, and E A Fedorova

UI MeSH Term Description Entries
D008777 Methyltestosterone A synthetic hormone used for androgen replacement therapy and as an hormonal antineoplastic agent (ANTINEOPLASTIC AGENTS, HORMONAL). 17 beta Methyltestosterone,17 beta-Hydroxy-17-methyl-4-androsten-3-one,17 beta-Methyltestosterone,17-Epimethyltestosterone,17-alpha-Methyltestosterone,17alpha-Methyl-Testosterone,17alpha-Methyltestosterone,17beta-Hydroxy-17-methyl-4-androsten-3-one,17beta-Methyltestosterone,Android (Methyltestoterone),Android-10,Android-25,Android-5,Mesteron,Mesterone,Metandren,Methitest,Oreton,Testoviron,Testred,Virilon,17 Epimethyltestosterone,17 alpha Methyltestosterone,17 beta Hydroxy 17 methyl 4 androsten 3 one,17alpha Methyl Testosterone,17alpha Methyltestosterone,17beta Hydroxy 17 methyl 4 androsten 3 one,17beta Methyltestosterone,Android 10,Android 25,Android 5
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011270 Pregnancy, Animal The process of bearing developing young (EMBRYOS or FETUSES) in utero in non-human mammals, beginning from FERTILIZATION to BIRTH. Animal Pregnancies,Animal Pregnancy,Pregnancies, Animal
D003687 Dehydroepiandrosterone A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion. Dehydroisoandrosterone,Prasterone,5-Androsten-3-beta-hydroxy-17-one,5-Androsten-3-ol-17-one,Androstenolone,DHEA,Prasterone, 3 alpha-Isomer,5 Androsten 3 beta hydroxy 17 one,5 Androsten 3 ol 17 one,Prasterone, 3 alpha Isomer
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D005333 Fetus The unborn young of a viviparous mammal, in the postembryonic period, after the major structures have been outlined. In humans, the unborn young from the end of the eighth week after CONCEPTION until BIRTH, as distinguished from the earlier EMBRYO, MAMMALIAN. Fetal Structures,Fetal Tissue,Fetuses,Mummified Fetus,Retained Fetus,Fetal Structure,Fetal Tissues,Fetus, Mummified,Fetus, Retained,Structure, Fetal,Structures, Fetal,Tissue, Fetal,Tissues, Fetal
D006128 Growth Gradual increase in the number, the size, and the complexity of cells of an individual. Growth generally results in increase in ORGAN WEIGHT; BODY WEIGHT; and BODY HEIGHT.
D000287 Administration, Topical The application of drug preparations to the surfaces of the body, especially the skin (ADMINISTRATION, CUTANEOUS) or mucous membranes. This method of treatment is used to avoid systemic side effects when high doses are required at a localized area or as an alternative systemic administration route, to avoid hepatic processing for example. Drug Administration, Topical,Administration, Topical Drug,Topical Administration,Topical Drug Administration,Administrations, Topical,Administrations, Topical Drug,Drug Administrations, Topical,Topical Administrations,Topical Drug Administrations
D000728 Androgens Compounds that interact with ANDROGEN RECEPTORS in target tissues to bring about the effects similar to those of TESTOSTERONE. Depending on the target tissues, androgenic effects can be on SEX DIFFERENTIATION; male reproductive organs, SPERMATOGENESIS; secondary male SEX CHARACTERISTICS; LIBIDO; development of muscle mass, strength, and power. Androgen,Androgen Receptor Agonist,Androgen Effect,Androgen Effects,Androgen Receptor Agonists,Androgenic Agents,Androgenic Compounds,Agents, Androgenic,Agonist, Androgen Receptor,Agonists, Androgen Receptor,Compounds, Androgenic,Effect, Androgen,Effects, Androgen,Receptor Agonist, Androgen,Receptor Agonists, Androgen

Related Publications

M I Golubeva, and L F Shashkina, and M V Starkov, and E A Fedorova
August 1974, Gigiena i sanitariia,
M I Golubeva, and L F Shashkina, and M V Starkov, and E A Fedorova
January 1993, Problemy endokrinologii,
M I Golubeva, and L F Shashkina, and M V Starkov, and E A Fedorova
January 1993, Eksperimental'naia i klinicheskaia farmakologiia,
M I Golubeva, and L F Shashkina, and M V Starkov, and E A Fedorova
January 1993, Eksperimental'naia i klinicheskaia farmakologiia,
M I Golubeva, and L F Shashkina, and M V Starkov, and E A Fedorova
January 1969, Biulleten' eksperimental'noi biologii i meditsiny,
M I Golubeva, and L F Shashkina, and M V Starkov, and E A Fedorova
January 1975, Farmakologiia i toksikologiia,
M I Golubeva, and L F Shashkina, and M V Starkov, and E A Fedorova
September 2016, Bulletin of experimental biology and medicine,
M I Golubeva, and L F Shashkina, and M V Starkov, and E A Fedorova
October 1990, Gigiena i sanitariia,
M I Golubeva, and L F Shashkina, and M V Starkov, and E A Fedorova
January 1976, Farmakologiia i toksikologiia,
M I Golubeva, and L F Shashkina, and M V Starkov, and E A Fedorova
April 1967, Nihon Naibunpi Gakkai zasshi,
Copied contents to your clipboard!